EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Glimepiride and Metformin Fixed-Dose Combination (FDC) along with Metformin + Dapagliflozin + Sitagliptin FDC in T2DM Patients with High Risk for Cardiovascular Disease: GRACE-CVD Study

L. S. Murthy, Anuj Jain, Lavanya Katakam, Arpandev Bhattacharyya, K. N. Sait, Mahesh Chavan, Manoj Chitale, Sonali Bhojane, Ashish Sardar, Ashish Prasad

Journal of Diabetology · 2026-05 · 17 (3) · 243-249

DOI: 10.4103/jod.jod_142_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetology, online erschienen am 22.05.2026. Verfasst von L. S. Murthy und 9 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cardiovascular complications are a major cause of morbidity and mortality in individuals with type 2 diabetes mellitus (T2DM). Fixed-dose combinations (FDCs) of antidiabetic agents may improve glycemic control, cardiovascular outcomes, and treatment adherence. However, real-world evidence in high cardiovascular risk settings is limited.

Objective

The GRACE-CVD study evaluated the effectiveness, tolerability, and physician-reported outcomes of dual FDC (Metformin + Glimepiride) and triple FDC (Metformin + Dapagliflozin + Sitagliptin) in T2DM patients with established or high cardiovascular disease (CVD) risk. Materials and Methods: This retrospective, multicenter study analyzed 1772 adult T2DM patients from 150 Indian centers. Patients had either established CVD or high CVD risk. Key parameters, including HbA1c, fasting and postprandial blood glucose, blood pressure, lipid profile, renal function, weight, and adverse events, were assessed over an average follow-up of 4.1 ± 3.1 months. Adherence, satisfaction, and reasons for prescribing FDCs were also captured.

Results

Both FDC regimens significantly improved glycemic outcomes, with HbA1c of

Zitieren

APA

Murthy, L. S., Jain, A., Katakam, L., Bhattacharyya, A., Sait, K. N., Chavan, M., Chitale, M., Bhojane, S., Sardar, A., & Prasad, A. (2026). Glimepiride and Metformin Fixed-Dose Combination (FDC) along with Metformin + Dapagliflozin + Sitagliptin FDC in T2DM Patients with High Risk for Cardiovascular Disease: GRACE-CVD Study. Journal of Diabetology, 17(3), 243-249. https://doi.org/10.4103/jod.jod_142_25

Vancouver

Murthy LS, Jain A, Katakam L, Bhattacharyya A, Sait KN, Chavan M, et al. Glimepiride and Metformin Fixed-Dose Combination (FDC) along with Metformin + Dapagliflozin + Sitagliptin FDC in T2DM Patients with High Risk for Cardiovascular Disease: GRACE-CVD Study. Journal of Diabetology. 2026;17(3):243-249. doi:10.4103/jod.jod_142_25

BibTeX
@article{Murthy2026,
  author = {Murthy, L. S. and Jain, Anuj and Katakam, Lavanya and Bhattacharyya, Arpandev and Sait, K. N. and Chavan, Mahesh and Chitale, Manoj and Bhojane, Sonali and Sardar, Ashish and Prasad, Ashish},
  title = {Glimepiride and Metformin Fixed-Dose Combination (FDC) along with Metformin + Dapagliflozin + Sitagliptin FDC in T2DM Patients with High Risk for Cardiovascular Disease: GRACE-CVD Study},
  journal = {Journal of Diabetology},
  year = {2026},
  volume = {17},
  number = {3},
  pages = {243--249},
  doi = {10.4103/jod.jod_142_25}
}
Kostenlos starten →